Hypera Lines Up Brazilian Semaglutide Launch Next Year

As Firm Sees ‘Aggressive’ Generic Competition In Its Domestic Market

Speaking as Hypera delivered its full year-results, CEO Breno Oliveira has set out plans for the Brazilian firm to launch an Ozempic rival in its domestic market next year. Meanwhile, the company is dealing with increasingly aggressive local generic competition.

Hypera is lining up an Ozempic rival for launch in Brazil next year (Shutterstock)

Brazil’s Hypera does not intend to be left out of the race to compete with Ozempic (semaglutide) when generic rivals launch in its domestic market next year. Speaking during the firm’s full-year results call, CEO Breno Oliveira has set out the company’s plans to launch its own generic semaglutide, as well as offering expectations around pricing dynamics for the product.

Asked about Ozempic during the Q&A session of the results call, Oliveira noted that the brand’s patent was due to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Generics

Hikma Rides Price Gap as Novo’s Ozempic, Wegovy Costs Climb

 
• By 

Hikma is seeing increased US demand for its generic Victoza (liraglutide) after the end of semaglutide compounding lifted prices for Novo Nordisk’s Ozempic and Wegovy. Meanwhile, the company is not for now pursuing semaglutide generics in the US or EU due to patent protection, but is targeting MENA.

Lupin Launches Generic Version Of Lilly’s Discontinued Glucagon In The US

 

Alongside biosimilars, Lupin sees injectable products as one of the key growth drivers in the US, as competition for two of its “material” drugs and proposed tariffs are looming over the firm.

Arizonans To Be Offered Up To 80% Discount On Generic Drugs

 

Arizona’s governor Katie Hobbs pointed to Trump’s One Big Beautiful Bill and other federal failures as she signed an executive order to increase access to medications in her state.

Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals

 
• By 

Viatris and Amphastar are expanding their complex generic portfolios with the planned launches of FDA-approved versions of Vifor Pharma/Daiichi Sankyo’s Venofer (iron sucrose). The FDA’s database also show Sandoz holds an approval for generic Venofer, though it has not disclosed launch plans.

More from Business

Amgen Welcomes Evolving Biosimilar Guidelines As Competitive Advantage

 
• By 

Amgen sees potential regulatory shifts toward streamlined biosimilar approvals as favorable, citing its strength in developing high-quality products.

‘Made-In-America’ Amneal Does Not Fear Trump’s Proposed ‘Chaotic’ Triple-Digit Tariffs On Drugs

 

As Amneal reports another solid quarterly performance, with refinanced debt and adjusted financial guidance for the year, will Trump’s “chaotic” tariffs shake it all up?

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.